Skip to main navigation

Home
Overview
News & Events
- News Releases
- Presentations
Stock Information
- Stock Quote & Chart
Corporate Governance
SEC Filings
- SEC Filings
IR Resources

Unsubscribe from all Obsidian Therapeutics
email alerts

Unsubscribe from all Obsidian Therapeutics email alerts

Email Address

Leave this field blank

Investor Contact

Contact

Caroline Code
VP, Corporate Development & Investor Relations
ir@obsidiantx.com

Subscribe to our Email Alerts

Email Address Required

Home
About Us
Our Science
Our Lead Clinical Program
Investors & Media
Join Our Team
Contact

Privacy
Terms of Use

© 2026 Obsidian Therapeutics. All Rights Reserved.

Our programs, including OBX-115, and cytoDRIVE® Platform are investigational and have not been approved by the FDA or any other regulatory agency.

Search Investors

Search this site